These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22118556)

  • 1. Predicting the unpredictable: autoantibody profile as parameter to foretell individual responses to infliximab treatment?
    Schön MP
    Br J Dermatol; 2011 Dec; 165(6):1160-1. PubMed ID: 22118556
    [No Abstract]   [Full Text] [Related]  

  • 2. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction.
    Hoffmann JH; Hartmann M; Enk AH; Hadaschik EN
    Br J Dermatol; 2011 Dec; 165(6):1355-8. PubMed ID: 21801160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab.
    Rodríguez-Jiménez P; Chicharro P; Godoy A; Llamas-Velasco M; García M; Daudén E
    Br J Dermatol; 2017 Sep; 177(3):862-863. PubMed ID: 28508387
    [No Abstract]   [Full Text] [Related]  

  • 4. Long persistence of tumour necrosis factor-α antagonist-induced autoantibodies under subsequent treatment with ustekinumab but no adverse effects: a case study of 14 patients with psoriasis.
    Hoffmann JHO; Knoop C; Enk AH; Hadaschik EN
    Br J Dermatol; 2018 Jan; 178(1):e9-e10. PubMed ID: 28581119
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis.
    Bito T; Nishikawa R; Hatakeyama M; Kikusawa A; Kanki H; Nagai H; Sarayama Y; Ikeda T; Yoshizaki H; Seto H; Adachi A; Horikawa T; Oka M; Nishigori C
    Br J Dermatol; 2014 Apr; 170(4):922-9. PubMed ID: 24329764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis.
    Takahashi H; Tsuji H; Ishida-Yamamoto A; Iizuka H
    J Dermatol; 2013 Jan; 40(1):39-42. PubMed ID: 23039179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of antinuclear autoantibodies in patients with psoriasis treated with anti-tumor necrosis factor-alpha agents: a retrospective long-term study.
    Saraceno R; Specchio F; Torres T; Nisticò SP; Rizza S; Chimenti S
    J Am Acad Dermatol; 2012 May; 66(5):e180-2. PubMed ID: 22507590
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study.
    Adişen E; Aral A; Aybay C; Gürer MA
    J Dermatol; 2010 Aug; 37(8):708-13. PubMed ID: 20649712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment.
    Bobbio-Pallavicini F; Alpini C; Caporali R; Avalle S; Bugatti S; Montecucco C
    Arthritis Res Ther; 2004; 6(3):R264-72. PubMed ID: 15142273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
    Reich K; Nestle FO; Papp K; Ortonne JP; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE;
    Lancet; 2005 Oct 15-21; 366(9494):1367-74. PubMed ID: 16226614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of biologics in psoriasis.
    Kamata M; Tada Y
    J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H; Nakagawa H;
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-NuMA antibodies in a psoriatic patient: considerations about clinical relevance and effect of infliximab treatment.
    Tampoia M; Mastrandrea V; Cassano N; Vena GA
    Immunopharmacol Immunotoxicol; 2009; 31(1):127-9. PubMed ID: 19951065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of the development of antinuclear antibodies during infliximab treatment.
    Saraceno R; Chimenti MS; Chimenti S
    J Am Acad Dermatol; 2013 Aug; 69(2):314. PubMed ID: 23866868
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis.
    Wahie S; Alexandroff A; Reynolds NJ
    Clin Exp Dermatol; 2006 May; 31(3):460-1. PubMed ID: 16681606
    [No Abstract]   [Full Text] [Related]  

  • 16. Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva).
    Thielen AM; Barde C; Saurat JH
    Br J Dermatol; 2006 Oct; 155(4):846-7. PubMed ID: 16965444
    [No Abstract]   [Full Text] [Related]  

  • 17. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis.
    Kui R; Gál B; Gaál M; Kiss M; Kemény L; Gyulai R
    J Dermatol; 2016 Sep; 43(9):1018-23. PubMed ID: 26892625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antinuclear antibodies do not predict anti-infliximab antibody induction in sarcoidosis.
    Vorselaars AD; Hijdra D; van Moorsel CH; Claessen AM; Grutters JC
    J Am Acad Dermatol; 2013 Aug; 69(2):312-4. PubMed ID: 23866866
    [No Abstract]   [Full Text] [Related]  

  • 20. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
    Cozzani E; Burlando M; Parodi A
    G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.